Form 4 for NMRA Neumora Therapeutics, Inc.

Accepted 2023-09-19 00:00:00 ET · period of report 2023-09-19 · accession 0001610717-23-000289 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2023-09-19	2023-09-19	NMRA	AMGEN INC	10%	C - Cnv Deriv	—	+33.60M	33.60M	New	—
D	2023-09-19	2023-09-19	NMRA	AMGEN INC	10%	P - Purchase	$17.00	+1.76M	35.37M	+5%	+$30.00M
DM	2023-09-19	2023-09-19	NMRA	AMGEN INC	10%	C - Cnv Deriv	—	-33.60M	0	-100%	—

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2023-09-19	C	A	33,603,948	—	33,603,948	D	—	—	(F1) The shares of Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering.
2	Common	Common Stock	2023-09-19	P	A	1,764,705	$17.00	35,368,653	D	—	—
3	Derivative	Series B Preferred Stock	2023-09-19	C	D	849,657	—	0	D	— · — to —	849,657 Common Stock	(F1) The shares of Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering.
4	Derivative	Series A-2 Preferred Stock	2023-09-19	C	D	32,754,291	—	0	D	— · — to —	32,754,291 Common Stock	(F1) The shares of Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering.